Cosmo Pharmaceuticals NV

C43

Company Profile

  • Business description

    Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

  • Contact

    Sir John Rogerson’s Quay
    Riverside II
    Dublin2
    IRL

    T: +353 18170370

    E: [email protected]

    https://www.cosmopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    339

Stocks News & Analysis

stocks

Is this ASX share a long-term buy?

Current operating conditions are challenging but over the long-term prospects are better.
stocks

Why Guzman and Reece's share reversals have a lot in common

Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks

Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?

Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,477.3020.70-0.24%
CAC 408,137.2686.191.07%
DAX 4022,732.24321.971.44%
Dow JONES (US)43,758.96137.800.32%
FTSE 1008,722.0353.360.62%
HKSE23,787.93753.913.27%
NASDAQ19,196.80170.410.90%
Nikkei 22538,142.3795.42-0.25%
NZX 50 Index12,452.46145.191.18%
S&P 5005,991.4536.200.61%
S&P/ASX 2008,240.7011.20-0.14%
SSE Composite Index3,380.2134.171.02%

Market Movers